| Literature DB >> 16480864 |
Xavier Barril1, Mandy C Beswick, Adam Collier, Martin J Drysdale, Brian W Dymock, Alexandra Fink, Kate Grant, Robert Howes, Allan M Jordan, Andrew Massey, Allan Surgenor, Joanne Wayne, Paul Workman, Lisa Wright.
Abstract
Novel piperazinyl, morpholino and piperidyl derivatives of the pyrazole-based Hsp90 inhibitor CCT018159 are described. Structure-activity relationships have been elucidated by X-ray co-crystal analysis of the new compounds bound to the N-terminal domain of human Hsp90. Key features of the binding mode are essentially identical to the recently reported potent analogue VER-49009. The most potent of the new compounds has a methylsulfonylbenzyl substituent appended to the piperazine nitrogen, possesses an IC50 of less than 600 nM binding against the enzyme and demonstrates low micromolar inhibition of tumour cell proliferation.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16480864 DOI: 10.1016/j.bmcl.2006.01.099
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823